BR112014008456A2 - regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais - Google Patents

regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais

Info

Publication number
BR112014008456A2
BR112014008456A2 BR112014008456A BR112014008456A BR112014008456A2 BR 112014008456 A2 BR112014008456 A2 BR 112014008456A2 BR 112014008456 A BR112014008456 A BR 112014008456A BR 112014008456 A BR112014008456 A BR 112014008456A BR 112014008456 A2 BR112014008456 A2 BR 112014008456A2
Authority
BR
Brazil
Prior art keywords
receptor
artificial transcription
transcription factors
endothelin
regulation
Prior art date
Application number
BR112014008456A
Other languages
English (en)
Inventor
Neutzner Albert
Huxley Alice
Flammer Josef
Original Assignee
Aliophtha Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliophtha Ag filed Critical Aliophtha Ag
Publication of BR112014008456A2 publication Critical patent/BR112014008456A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais". a presente invenção refere-se a um fator de transcrição artificial compreendendo uma proteína de dedo de zinco polidáctila que tem como alvo especificamente um promotor de gene de receptor fusionado a um domínio de proteína inibidor ou ativador, uma sequência de localização nuclear e um domínio de transdução de proteína. em exemplos particulares, esses promotores de genes de receptores regulam a expressão do receptor de endotelina a, do receptor de endotelina b, do receptor do tipo toll 4 ou do receptor de ige de alta afinidade. fatores de transcrição artificiais dirigidos para os receptores de endotelina a ou b são úteis no tratamento de doenças moduladas pela endotelina, como doenças cardiovasculares, e, em particular, doenças do olho, por exemplo, oclusão da veia retiniana, oclusão da artéria retiniana, edema macular, neuropatia óptica, coriorretinopatia serosa central, retinite pigmentosa, neuropatia óptica hereditária de leber, e outras. fatores de transcrição artificiais dirigidos para o receptor do tipo toll 4 ou receptor de ige são úteis para o tratamento de transtornos autoimunes, e outros, e transtornos alérgicos, respectivamente.
BR112014008456A 2011-10-11 2012-10-10 regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais BR112014008456A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number Publication Date
BR112014008456A2 true BR112014008456A2 (pt) 2017-04-11

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008456A BR112014008456A2 (pt) 2011-10-11 2012-10-10 regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais

Country Status (20)

Country Link
US (1) US20140296129A1 (pt)
EP (1) EP2766484A2 (pt)
JP (1) JP2014530607A (pt)
KR (1) KR20140079780A (pt)
CN (1) CN103998609A (pt)
AU (1) AU2012323032A1 (pt)
BR (1) BR112014008456A2 (pt)
CA (1) CA2851560A1 (pt)
CL (1) CL2014000897A1 (pt)
CO (1) CO6930308A2 (pt)
EA (1) EA201490531A1 (pt)
HK (1) HK1197083A1 (pt)
IL (1) IL231865A0 (pt)
IN (1) IN2014CN02586A (pt)
MA (1) MA36970A1 (pt)
MX (1) MX2014004331A (pt)
SG (1) SG11201400701WA (pt)
TN (1) TN2014000117A1 (pt)
WO (1) WO2013053719A2 (pt)
ZA (1) ZA201401960B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073091A (zh) 2014-09-07 2017-08-18 西莱克塔生物科技公司 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
JP7427584B2 (ja) 2017-10-13 2024-02-05 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクターｉｇｍ応答を減弱化するための方法および組成物
WO2019195285A1 (en) * 2018-04-02 2019-10-10 University Of Miami Ifn-beta reporter system for immortalized primary cells
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
WO2021169333A1 (zh) * 2020-02-25 2021-09-02 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4118327B2 (ja) * 1994-08-20 2008-07-16 ゲンダック・リミテッド Ｄｎａ認識のための結合タンパク質におけるまたはそれに関連する改良
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2001052620A2 (en) * 2000-01-21 2001-07-26 The Scripps Research Institute Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
CA2442293A1 (en) * 2001-02-21 2002-08-29 Novartis Ag Zinc finger binding domains for nucleotide sequence ann
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
AU2006297259A1 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of toll-like receptors on stem cells
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
EP2411518A2 (en) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina)
EP2509594A1 (en) * 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Also Published As

Publication number Publication date
IN2014CN02586A (pt) 2015-08-07
KR20140079780A (ko) 2014-06-27
WO2013053719A3 (en) 2013-06-27
MA36970A1 (fr) 2016-03-31
US20140296129A1 (en) 2014-10-02
ZA201401960B (en) 2015-06-24
HK1197083A1 (en) 2015-01-02
WO2013053719A2 (en) 2013-04-18
CN103998609A (zh) 2014-08-20
MX2014004331A (es) 2014-11-26
AU2012323032A1 (en) 2014-04-03
IL231865A0 (en) 2014-05-28
CA2851560A1 (en) 2013-04-18
CO6930308A2 (es) 2014-04-28
JP2014530607A (ja) 2014-11-20
EA201490531A1 (ru) 2014-08-29
EP2766484A2 (en) 2014-08-20
SG11201400701WA (en) 2014-08-28
TN2014000117A1 (en) 2015-07-01
CL2014000897A1 (es) 2014-11-21

Similar Documents

Publication Publication Date Title
BR112014008456A2 (pt) regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais
DOP2016000280A (es) Vectores de aav para la terapia génica de la retina y el snc
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
AR081361A1 (es) Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
UY37636A (es) Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1
AR092317A1 (es) Vectores virales para el tratamiento de distrofia retiniana
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
PH12020550748A1 (en) Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium
BR112014027227A2 (pt) modificação alvejada de malato desidrogenase
WO2010048352A3 (en) Methods for treating eye disorders
MX2022006948A (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
PH12015502421A1 (en) Artificial transcription factors engineered to overcome endosomal entrapment
BR112012008084A2 (pt) método terapêuticos e composições.
BR112014016238A2 (pt) método para aumentar rendimento de planta e composições de aperfeiçoamento de rendimento
Wu et al. RNAi screening identifies GSK3β as a regulator of DRP1 and the neuroprotection of lithium chloride against elevated pressure involved in downregulation of DRP1
BR112015021546A2 (pt) molécula de ácido nucleico isolada, cassete de expressão, vetor, célula vegetal, planta, semente transgênica, método para expressar uma sequência de genes em uma planta ou uma célula vegetal e método para expressão de uma sequência de nucleotídeos de uma maneira preferencial para raiz em uma planta
Chen et al. MicroRNA‐191‐5p ameliorates amyloid‐β1‐40–mediated retinal pigment epithelium cell injury by suppressing the NLRP3 inflammasome pathway
BR112015022495A2 (pt) promotores de feijão-soja constitutivos
TN2015000436A1 (en) Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency
Rothuizen et al. Promoting tropoelastin expression in arterial and venous vascular smooth muscle cells and fibroblasts for vascular tissue engineering
BR112019005600A2 (pt) promotor de planta para expressão de transgene
BR112021017853A2 (pt) Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
BR112014029968A2 (pt) promotores induzíveis de plantas e seu uso
BR112018071095A2 (pt) promotores preferenciais em semente e funículo e usos dos mesmos
WO2014161884A3 (en) Artificial transcription factors regulating nuclear receptors and their therapeutic use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]